Page last updated: 2024-10-31

nemonapride and Parkinson Disease

nemonapride has been researched along with Parkinson Disease in 1 studies

N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide : A benzamide obtained by formal condensation of the carboxy group of 5-chloro-2-methoxy-4-(methylamino)benzoic acid with the amino group of 1-benzyl-2-methylpyrrolidin-3-amine.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Seeman, P1
Guan, HC1
Van Tol, HH1
Niznik, HB1

Other Studies

1 other study available for nemonapride and Parkinson Disease

ArticleYear
Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Synapse (New York, N.Y.), 1993, Volume: 14, Issue:4

    Topics: Animals; Benzamides; Corpus Striatum; Dopamine D2 Receptor Antagonists; Humans; In Vitro Techniques;

1993